PRKN and Parkinson disease: Pre-clinical changes identified by neuroimaging studies and a reduced fluorodopa uptake in the striatum previously observed in asymptomatic heterozygous PRKN mutation carriers also support an increased risk of developing PD symptoms in heterozygous PRKN mutation carriers (34, 35).